

Complex Serology

Matt Hazell – Senior Clinical Scientist (HSST) Red Cell Immunohaematology NHSBT








The Tool kit







Transfusion STULL MÖTTERS


 Mo
 C
 U
 E
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I
 I

Screen

AB A

Group

- 54 YO Female patient
 - O neg rr K neg
 - History of pregnancy and transfusion
 - 3 Cell screen positive



Transfusion STULI MÖTTERS

 Hb
 C
 B
 E
 C
 B
 C
 B
 C
 FI
 K
 L
 G

 1
 R/%
 +
 +
 0
 0
 +
 +
 +
 +
 0
 0


 2
 R/%
 +
 +
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 0
 +
 +
 0
 +
 +
 0
 +
 +
 0
 +
 0
 +</

Screen

AB A


Group

- 54 YO Female patient
 - O neg rr K neg
 - History of pregnancy and transfusion
 - Myeloma Isatuximab



- 54 YO Female patient
 - O neg rr K neg
 - History of pregnancy and transfusion
 - Myeloma Isatuximab


										<u>.</u>													_
	Rh	M	N	S	S	P1.	Lua	К.	, k	Kp ^a	Lea	Leb	Fya	Fyb	Jkº	Jk⊳	Other		ENTIAT	DIT	5-033	ИĽ	Pan
1	R1"R1	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		3	3	0	0	0	(1, 2
2	R ₁ R ₁	+	0	+	0	4	0	. +	+	0	+	0	. +	0	+	0		3	3	0	P	0	_ (-/ -
3	R ₂ R ₂	0	+	0	+	3	.0	0	+	0	0	÷	0	+	+	0	HLA+ Doa-b+	4	3	0	0	W	
4	r°r	Q	+	0	+	0.	0	0	+	0	0	+	+	0	+	+		3	3	0	0	0	
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		3	3	0	0	0	
6	rr	+	0	0	+.	2	0	+	0	0	0	+	0.	+	0	+	-	3	3	0	W	0	
7	гт	0	+	0	÷	1	0	+	+	0	+	0	0	+	+	0		2	3	0	0	D	A
8	rr	+	0	0	+	0	Ó	0	+	+	0	Ŧ	+	0	0	+	Cob+	3	3	0	12	0	
9	rr	0	+	+	0	4	0	0	.+	0	0	+	0	+	Ö	+		3	3	0	W	0	-
10	irr	+	0	0	+	4	+	0	+	0	0	+	÷	0	+	0	Cob+	3	3	0	$\dot{\Omega}$	W	
			18														Auto	0					
																.8	Weak control	3	3	3	3	3	
	1	1	1	F	1	1							-	1				1	1				
																							Pł
			lg(3		lg	A			IgM		1	C	3c		C	C3d	Ctl					
		T	0	10	1	0)			D			f	7			0	D		_			
		+			<u></u>			1		-				<u></u>				~					
										•							•						



Transfusion STILL MÖTTERS

Transfusion STUL MÖTTERS

- 32 YO Female patient with Sickle Cell Disorder
 - Patient presents with Crises
 - Partial exchange 6 days ago
 - Hb 43g/L, after exchange it was 80g/L



Rh

RIWR1

R_IR₁

R2R2

r'r

r"r

rr

rr

rr

ET.

rr.

1

2

3

4

5

6

7

8

9

10

M

0

+

0

0

+

+

0

+

0

+

N

÷

0

+

+

0

0

+

0

 $^{+}$

0

lgG

4

S

0

+

0

0

÷

0

0

0

+

0

• 32 YO Female patient with Sickle Cell Disorder

Patient presents with Crises

P1.

Û

4

3

0.

0

2

1

0

4

4

lgA

0

Lua

0

0

0

0

0

0

0

0

0

+

s

+

0

+

+

0

+

+

+

0

÷

- Partial exchange 6 days ago
- After exchange it was 80g/L; now = Hb 43g/L

Kpa

0

0

0

0

0

0

0

+

0

0

Les

+

+

0

0

Ò

0

+

0

0

0

C3c

Leb

0

0

+

+

+

+

0

+

+

+

Fy^a

0

+

0

+

+

0

0

+

0

+

Ey^b.

+

0

+

0

0

+

+

0

+

0

C3d

0

Jka.

0

+

+

+.

0

0

+

0

0

+

Jkb

+

0

0

+

+

+

0

+

+

0

Ctl

D

Other

HLA+ Doa-b+

Cob+

Cob+

Auto

Weak control

• O pos Ro K neg, Screen = panreactive

0

+

0

0

0

÷

+

0

0

0

lgM

0

k

+

+

+

÷

+


0

+

+

+

+



• 32 YO Female patient with Sickle Cell Disorder

- Patient presents with Crises
 - Partial exchange 6 days ago
 - After exchange it was 80g/L; now = Hb 43g/L
 - O pos Ro K neg, Screen = panreactive
 - Panel = Panreactive $(I\Delta T/Enz I\Delta T)$

		_					ı a						/ []			/											
			Lot	Numbe	er	Rh	0	:	D	E		;	e	C*	ł	(Jka	Jkb							, Por		
			R40	5 3591	,	R ₁ R ₁	4		*	0)	+	0)	+	0						Panel (IAT, EnziA		DAT	
			1.5.7.5			rr	C		0	0	-		+	0	4	•	0	+			N. 0 Y I - 64		UZU.UU.	(1, 2, R1R1, R2R2, DT1	r) 	DAI	
	Rh	M	N	S	s	P1.	. Luª	ĸ	k	Кря	Lea	Leb	Fya	Ey ^b	Jka	Jkb	1	Other		10.00			AAZ				
1	R ₁ ^w R ₁	0	+	0	+	0	_0	0	+	0	+	0	0	+	0	+			4	4	2	2	0		PROTEIN		
2	R ₁ R ₁	+	0	+	0	4	0	+	+	0	+	0	+	0	+	0	-		4	4	2	D	ō			() H	
3	R2R2	0	+	0	+	3	0	0	+	0	0	+	0	+	+	0	HL	A+ Doa-b+	4	4	2	0	0		Inhibition		
4	r"r	0	+	0	+	0.	0	0	+	0	0	+	+	0	+.	+			4	4-	2	2	0	Adsorption		Rare cell	
5	r"r	+	0	+	0	0	0	0	+	0	Ó	+	+	0	0	+			4	4	2	2	Ō	Elution	Neutralisatio	n	
6	rr	+	0	0	+	2	0	+	0	0	0	+	0'	+	0	+			4	4	2	2	ō				
7	rr	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0			4	4	2	5	ō		°-1	ΠП	
8	ŕr	+	0	0	+	0	0	0	+	+	0	.+	+	0	0	+		Cob+	4	4	2	2	0				
9	rr	0	+	+	0	4	0	0	+	0	0	+	0	+	0	+			4	4	2	2	0				
10	rr	.+	0	0	+	4	+	0	+	0	0	+	+	0	+.	0		Cob+	4	4	2	0	0	Dhanatuna		Donath	
-		-																Auto	a					Phenotype	Genotyping	Landsteiner	
		ļ														•	N	leak control	3	3	3	3			- 0		
	1	1	۰. ۳۳۰		~							1			[W//ba	t'c n	NV	
			-	lg	6		IgA	18. ₁₉ .	-	lgM			C3c			23d		Ctl								ext	H
			1	L	t	<u> </u>	0		<u> </u>	$\underline{\circ}$			0			2		0									
										1						1											

Transfusion STILL MÖTTEI

Group


MATTERS

Screen

• 32 YO Female patient with Sickle Cell Disorder

- Patient presents with Crises
 - Partial exchange 6 days ago
 - After exchange it was 80g/L; now = Hb 43g/L
 - O pos Ro K neg, Screen = panreactive
 - Panel = Panreactive (IAT/Enz IAT); anti-Jkb adsorption


Cell	ID	АВО	с	D	E	e	e	Cw	М	N	S	8	P 1	Lua	Lub	Lea	Leb	ĸ	k	Kpa	Kpb	Fya	Fyb	Jka	Jkb	Rarity	Additional types	IAT
1	NZ2392	0	0	+	0_	+	+	0	0	+	0	0	+	0	+	0_	+	-0		0	-+	0	-+	-	-0	U		0
2	NZ2401	0	0	0	0	+	+	0	+	+	0	+	+	0	0	+	0	0	+	0	+	+	+	+	0	Lu(a-b-) *	AnWj - HLA+	
3	NZ2385	0	0	+	+	+	+	0	+	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	+	Yta-	HLA+	4
4	NZ2036	0	٥	+	+	.+	0	0	. +	0	+	+	+	0	+	0	+	0	+	+	0	+	+	+	+	Kob-		4
5	NZ2378	Ó	0	0	0	+	+	0	+	0	io.	÷	0	D	+	0	*	+	+	0	+	+	0	0	+	Kna-	HLA+	4
6	NZ2402	0	+	+	0	+	+	0	+	0	+	+	+	0	+	0	+	0	+	0	+	0	+	+	0	-		
7	NZ2408	0	0	+	+	+	+	0	+	+	.0	+	0	0	+	0	+	0	+	0	+	0				Vel -		4
8	NZ2403	0	+	+	0	Q	+	+	0	+	0	+	+	0	+	+	0	+	+	-			0	+	0	Jsb-		4
9	NZ2311	0	+	+	0	+	+	0	+	+	+	+	+	0	+	0	+			0	+	+	0	0	+	Co(a-b+)		4
10	NZ2363	0	0	0	0	+	+	0	+	0	+	0		-		-	_	0	+	0	+	+	0	0	+	Wra+	Vel+	4
11	NZ2279		_		_								0	0	+	0	_	0	+	0	+	0	+	+	0	Ch-		4
	1.00	0	0	0	0	+	+	0	0	+	0	+	+	0	+	0	+	+	+	0	+	0	+	+	0	Rg-		4
12	NZ2314	0	0	+	+	+	+	0	+	0	0	+	+	0	+	+	Q	0	÷	0	+	+	+	-	÷	Bombay		4
13	NZ2433	0	Ó	+	+	+	+	0	0	+	+	+	w	0	+	0	0	0	+	0	+	+	w	+	+	D+ cord \$		4
14	NZ2434	0	0	σ	o	+	+	0	0	+	0	+	0	0.	+	0	0	0	+	0	+	w	0	+		D- cord \$		4
15	NZ9999																	-	_			-+						-
					L			·	1		1															weak	control	3




Transfusion

MATTERS

- 32 YO Female patient with Sickle Cell Disorder
- Patient presents with Crises
 - Partial exchange 6 days ago
 - After exchange it was 80g/L; now = Hb 43g/L
 - O pos Ro K neg, Screen = panreactive
 - Panel = panreactive (IAT/Enz IAT); anti-Jkb adsorption
 - Rare cell ?anti-U
 - Patient RBC Genotype
 - *JK*01 = Positive*
 - *JK*02 = Negative*
 - GYPB*03 = Negative
 - GYPB*04 = Negative
 - Predicted phenotype = ?




- 32 YO Female patient with Sickle Cell Disorder
- Patient presents with Crises
 - Partial exchange 6 days ago
 - After exchange it was 80g/L; now = Hb 43g/L
 - O pos Ro K neg, Screen = panreactive
 - Panel = panreactive (IAT/Enz IAT); anti-Jkb adsorption
 - Rare cell ?anti-U
 - Patient RBC Genotype
 - *JK*01 = Positive*
 - *JK*02 = Negative*
 - GYPB*03 = Negative
 - GYPB*04 = Negative
 - Predicted phenotype = Jk (a+, b-); S-, s-, U-






- 68 YO male patient; revision of total hip replacement
 - No underlying conditions
 - Group O pos, antibody screen neg, 2 units issued by EI
 - Halfway through 2nd = rigors, foreboding feeling of impending doom, haemoglobin urea; transfusion stopped and investigation undertaken
 - What tests should be performed?






- 68 YO male patient; revision of total hip replacement
 - No underlying conditions
 - Group O pos, antibody screen neg, 2 units issued by EI
 - Halfway through 2nd = rigors, foreboding feeling of impending doom, haemoglobin urea; transfusion stopped and investigation undertaken
 - What tests should be performed?
- Pre and post samples
 - Group and screen; Panel (IAT and Enz IAT)
 - DAT; If positive elution
 - XM against units



- 68 YO male patient; revision of total hip replacement
 - No underlying conditions
 - Group O pos, antibody screen neg, 2 units issued by EI
 - Halfway through 2nd = rigors, foreboding feeling of impending doom, haemoglobin urea; transfusion stopped and investigation undertaken
 - Which is?????
- Pre and post samples

Group = O pos; Screen = negative; IAT and Enz IAT = negative





Screen

Rare cell

Donath

Landsteiner

- 68 YO male patient; revision of total hip replacement
 - No underlying conditions
 - Group O pos, antibody screen neg, 2 units issued by El
 - Halfway through 2nd = rigors, foreboding feeling of impending doom, haemoglobin urea; transfusion stopped and investigation undertaken
 - Which is?????

9 1

10 | rr

D

÷

+

0

+

0

0

+

4

4

0

+

0

0

+

+

0

0

C3d

00

0

0

Pre and post samples

Group = O pos; Screen = negative; IAT and Enz IAT = negative N P1 Rb Lua Kpa s Lea Leb Fya Fy^h. Jka Jk^b. Other HAT EARIAT IAT ENTIMI 1 R1"R1 0 + 0 ÷ 0 0 0 ÷ 0 + 0 0 + 0 ÷ 0 0 Ð Õ 0 Ó 2 R₁R₁ + + 0 4 0 + ÷ 0 + 0 0 + D Ó + 0 0 0 0 3 R₂R₂ 0 + 0 ÷ 3 0 0 + 0 0 S + 0 + 0 O 0 0 + HLA+ Doa-b+ 0 + Ō 4 r'r 0 + 0 0 +0 0 0 0 0 Ō + 0 + 0 + + 0 - 5 r"r 0 ÷ 0 0 + 0 0 + 0 0 + 0 0 D 0 + 0 0 + 0 0 + 0 2 + 0 6 rr 0 + 0 0 0 Ō 0 + 0 + 0 C 0 + 7 + 0 1 0 + 0 rr. ÷ 0 + + 0 0 D 0 Ō + + 0 0 0 8 + 0 0 0 +. rr 0 + 0 + 0 9 0 + + 0 0 + Cob+

÷

+

0

+

Ctl

1

+

0

0

+

+

0

0

0

O

3

PRE

Cob+


Weak control

Prez O

0


O

3




Transfusion STILL MÖTTERS


- 60 yo male patient with MDS
 - Attending for routine Tx Hb = 54g/L
- Grouping normal, screen giving variable reactivity



Transfusion STILL MÖTTERS

- 60 yo male patient with MDS
 - Attending for routine Tx Hb = 54g/L
- Group fine, screen giving variable reactivity






Transfusion STULI MÖTTERS

- 60 yo male patient with MDS
 - Attending for routine Tx Hb = 54g/L
- Group fine, screen giving variable reactivity
- Not resolved with LISS and phenotype pos generally


	Rh	M	N	S	5	P1	Lua	ĸ	. K	Kpa	Lea	Leb	Fy	Fy ^b	Jk*	Jkb	Other	IAT	52 M	1455
1	R1 ^m R1	0	+	0	÷	0	0	0	+	0	+	0	0	+	0	+		1	0	1
2	R ₁ R ₁	+	0	+	0.	4	0	+	+	0	+	0	. +	0	+	0		W	0	N
3	R ₂ R ₂	0	+	0	+	3	0	0	÷	0	0	+	0	+	+	0	HLA+ Doa-b+	2	0	
4	r'r	0	• +	0	+	0	0	0	+	0	0	+'	+	0	+	+		11	0	1
5	ר"ר	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		2	0	2
6	rr	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		2	0	1
7	rr	0	+	0	+	1	0	+	+	0	+	0	Ó	+	+	0		W	O	W
8	rr	+	0	Ő	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	L	0	0
9	m	0	+	+	0	4	0	.0	+	0	0	+	0	+	0	+		1	Ð	1
10	rr	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	W	0	W
																	Auto	O		
																	Weak control	3	3	
	PATIENT	+	+	+	+			+	+				+	+	+	+				





- 60 yo male patient with MDS
 - Attending for routine Tx Hb = 54g/L
- Group fine, screen giving variable reactivity
- Reactivity resolved with AB serum inhibition
- What is the antibody?


toront il later																						
	Rh	М	N	S	S	Pi	Lua	ĸ	. k	Kpa	Lea	Leb	Fy.	Fy ^b	Jkª	Jkb	Other	IAT.	EN IAT	1.155	ABRIER	PBS
1	R1"R1	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		1	0	1	0	1
2	R ₁ R ₁	+	0	+	0.	4	0	+	+	0	+	0	. +	0	+	0		W	0	N	0	2
3	R ₂ R ₂	0	+	0	+	3	0	0	+	0	0	+	0	+	+	0	HLA+ Doa-b+	2	Ö		0	2
4	r'r	0	+	0	+	0	0	0	+	0	0	+	+	0	+	+		11	Q	1	0	1
5	ד"ד	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		2	9	2	0	1
6	rr	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		2	0	1	0	2
7	rr	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0		w	0	W	0	W
8	rr	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	L	0	0	0	2
9	m	0	+	+	0	4	0	.0	+	0	0	+	0	+	0	+		1	Ð	1	0	3
10	rr	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	W	0	W	0	N
																	Auto	O				
																	Weak control	3	3			22
	PATIENT	+	+	+	+			+	+				+	+	+	+						
-	197,841	<u> </u>			+	+	↓		├ ──		+	- <u></u>		[L	-	1		1	ł	I	<u> </u>	L



Transfusion STULI MÖTTERS

- 60 yo male patient with MDS
 - Attending for routine Tx Hb = 54g/L
- Group fine, screen giving variable reactivity
- Reactivity resolved with AB serum inhibition
- What is the antibody = anti-Ch/Rg


ExiATLISS ABRIDA PBS Rh P1 Lua IAT. M N S Kpa Lea Leb Fy4 Eyb Jka Jkb Other R1"R1 0 + 0 ÷ 0 0 0 ÷ 0 + 0 0 + 0 1 + O O 0 + 2 R₁R₁ + 0 + 0 4 0 + + 0 + 0 + 0 W N N 0 3 R₂R₂ 0 ÷ 0 + 3 0 0 ÷ 0 0 + 0 + + 0 HLA+ Doa-b+ 2 0 + 4 ÷ 0 ÷ 0 0 0 0 0 $+^{\prime}$ + O 0 r'r 0 0 + + 0 0 0 0 0 ÷ 0 0 2 0 2 0 + + + + 5 r"r 0 0 + 0 0 2 0 + 0 0 + 2 0 0 0 + 0 6 rr + + 0 + 2 0 0 + 1 0 + + 0 O 7 FF 0 + + 0 Ó W + + 0 W W 0 + + 0 + 0 0 0 Ø 8 r + 0 0 + 0 + 0 0 + Cob+ L .0 0 Ø 0 9 rr 0 ÷ + 0 4 0 + 0 + 0 + 0 + 0 + 0 0 W 0 N 0 N 10 rr +0 0 ÷ 4 + + + 0 Cob+ + 0 Auto O 3 3 Weak control + + + + + + + + ATTIT +



Transfusion STULI MÖTTERS

- 4 YO presents with palor, anaemia, temperature following a history recurrent infection
- Hb = 55g/L
- O pos (R1R1 K neg);
- No history of Tx, medications or bleeding

	Rh	С	D	E	с	e	Cw	М	N	s	s	P1	ĸ	k	Kpª	Le ^a	Le ^b	Fyª	Fyb	Jkª	Jk ^b	Other
1	R₁ ^w R₁	+	+	0	0	+	+	+	0	+	+	+	+	+	0	0	+	+	0	0	+	0
2	R ₂ R ₂	0	+	. +	+	0	0	+	÷	0	+	+	0	+	+	0	+	0	+.	+	0	0
3	rr	0	0	0	+	3 + 1	0	+	0	+	0	+	0	+	0	+	0	0	+	+	0	0







- 4 yo presents with palor, anaemia, temperature following a history recurrent infection (cold like virus).
- Hb = 55g/L
- O pos (R1R1 K neg); AB screen neg
- No history of Tx, medications or bleeding

	lgG			lg	A				M				23c			C:	30	<u>c</u>
5	11			6)			<u> </u>	ر			<u>(</u>	<u>ノ</u>			٤		Ę
	Rh	M	N	S	s	P1.	Lua	ĸ	. k	Kpª	Leª	l.e ^b	Fy ^a	Fyb	Jkª	Jk ⁿ	Other	Elina
1	R ₁ ^w R ₁	.0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		0
2	R ₁ R ₁	+	0	÷	0	4	0	+	+	0	+	0	+	0	+	0		C
3	R ₂ R ₂	0	+	0	+	3	0	0	+	0	Ö	+	0	+	+	0	HLA+ Doa-b+	D
4	r'r	0	• +	0	+	0,	0	0	+	0	0	+	+	0	+	+		C
5	r"r	+	0	+	0	0	0	0	+	0	0	.+	+	0	0	+		C
6	п	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		D
7	m	0	+	0	+	1	0	+	+	0	+	0	0	+	+	0		C
8	m	+	0	0	+	0	Ö	0	+	+	0	+	+	0	0	+	Cob+	0
9	m	0	+	+	0	4	0	0	+	0	0	+	0	+	0	+		0
10	rr	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	C
																	Auto	
2																	Weak control	3





- 4 yo presents with palor, anaemia, temperature following a history recurrent infection (cold like virus).
 - Hb = 55g/L
 - O pos (R1R1 K neg); AB screen neg
 - No history of Tx, medications or bleeding
 - Donath Landsteiner investigation
 - What are the sampling requirements?






Panel (IAT, Enz IAT) (1, 2, R1R1, R2R2, DTT)

Flutio

Phenotype







Inhibition Neutralisation

n Rare cell








Vhat's next

Genotyping

- 4 yo presents with palor, anaemia, temperature following a history recurrent infection (cold like virus).
 - Hb = 55g/L
 - O pos (R1R1 K neg); AB screen neg
 - No history of Tx, medications or bleeding
 - Donath Landsteiner investigation
 - Sampling requirements Serum sample kept and warm separated
 - How do you perform the test?



Transfusion


MATTERS

STILL


- 4 yo presents with palor, anaemia, temperature following a history recurrent infection (cold like virus).
 - Hb = 55g/L
 - O pos (R1R1 K neg); AB screen neg
 - No history of Tx, medications or bleeding
 - Donath Landsteiner investigation
 - Sampling requirements Serum sample kept and warm separated
 - How do you perform the test?

0°C 37°C 37°C 37°C В В Α Α Α B 1hr 1hr Patient serum Pooled reagent Group O RBCs Complement added






- 4 yo presents with palor, anaemia, temperature following a history recurrent infection (cold like virus).
 - Hb = 55g/L
 - O pos (R1R1 K neg); AB screen neg
 - No history of Tx, medications or bleeding
 - Donath Landsteiner investigation
 - Sampling requirements Serum sample, warm separated (1, 2, R
 - How do you perform the test:







D

С

+ +

0 + + + 0 0 + + 0 + + 0 + + 0

Rh

R1WR1

R₂R₂

1

2

E

0 0

C

e Cw

+

- 32 YO female patient recently delivered had has experienced PPH
 - A pos It was her 3rd pregnancy and there were no previous problems in pregnancy,

P1 K k Kp^a Le^a Le^b

+ 0 0

Fyb Jka Jkb

+. + 0

0 0

+

Other

0

0

Fya

+ + +

+ 0


AB screen neg previously, but now positive

S

0 +

0 3 0 0 0 + + 0 ÷ 0 + 0 + 0 rr ÷ 0 0 0 ÷ 3+ AT GYMT M N S P1. Rh s Luª K Kp* Lea Leb Fy' F.yb Jk^a Jkb. Other RI"RI 0 + 0 +. 0 0 0 1 + 0 + 0 0 + 0 + 2 R₁R₁ + 0 Ŧ 4 0 0 + .+ 0 + 0 0 0 + 0 + 0 3 R2R2 0 ÷ 0 + 3 0 0 + 0 Ď 0 + + + 0 HLA+ Doa-b+ 0 Ο 4 r'r 0 ÷ 0 + 0 0 0 + 0 0 + + 3 0 + ÷ 5 5 7"7 0 0 + + 0 0 0 + 0 3 0 S + + 0 0 + 6 rr + 0 0 2 +' 0 + 0 0 0 + 0 +0 + 4 7 rr 0 ÷ 0 + 1 0 + ÷ 0 + 0 0 + + 0 4 8 rr + 0 0 0 + 0 0 + + 0 + 0 $\mathbf{+}$ Ó ÷ Cob+ 4 9 0 + + TT. D 4 0 0 ÷ 0 0 + 0 5 + 0 + 4 10 rr + 0 0 + 4 + 0 0 + 0 5 ÷ ú ÷ 0 + 0 Cob+ Auto 3 3 Weak control






- 32 YO female patient
 - Recently delivered had has experienced PPH
 - A pos It was her 3rd pregnancy and there were no previous problems in pregnancy,
 - AB screen neg previously, but now positive

N Rh М S Kp* JAT GUTAT Fyb Jkª Other RI"RI 0 1 + 0 + 0 0 0 + 0 + 0 0 0 + 0 0 + 2 R_1R_1 + 0 Ŧ 0 4 0 + .+ 0 + 0 + 0 0 0 + 0 3 R2R2 0 ÷ 0 + 3 0 0 + 0 D + 0 ÷ + 0 HLA+ Doa-b+ Ô 4 r'r 0 ÷ 0 + 0 0 0 + 0 0 + 0 3 + + 5 ÷ 5 T"T + 0 + 0 0 0 0 + 0 0 3 + + 0 0 + S 6 rr + 0 0 +' 2 Ö + 0 0 0 + 0 ÷ 0 + 4 7 rr 0 + 0 + 1 0 + ÷ 0 + 0 0 + + 0 5 U. 8 rr + 0 0 + 0 0 0 + + 0 + + 0 Ó + Cob+ 4 9 TT. 0 ÷ ÷ 0 4 0 0 + 0 0 + 0 + 0 + 4 10 rr + 0 0 + 4 + 0 + 0 0 0 + ÷ + 0 Cob+ ú S М N S P1 Lua κ Rh s k Kpa Lea Leb Fy^a Fy Jka Jkb Other AT R1wR1 0 + 0 + 3 0 0 + 0 0 + Ò + 0 + HLA+ 1 O 2 R1wR1 + 0 + 0 0 0 0 + 0 0 + ÷ 0 + 0 Ð 3 0 + 0 R1RZ + + + 0 0 0 0 0 + + 0 0 + 4 RZr' + + 0 + 0 0 0 + 0 + 0 + 0 0 0 + 5 Ror 0 + 0 + 3 0 0 + 0 0 + 0 0 + 0 40 **R1R1** + + 0 + 0 0 + 0 6 0 0 + + 0 + 0 0 7 **R1R1** ÷ 0 + 0 0 0 + + 0 0 0 0 0 w + 8 R1r' 0 + ٥ + 2 0 0 + + + 0 0 + 0 + HLA+ 0 0 3 + 0 + 9 **R1R1** + 0 + + 0 Û + 0 0 + Bga+ w 10 **R1R1** 0 0 0 0 + 0 + 0 0 w 0 0 ÷






Rh and K type = R1R2 K neg – What would you transfuse?

Case 7

- 77 YO male patient man with CLL
 - Regularly transfused every 2 weeks
 - B pos; antibody screen positive


	1					T			7	1	<u> </u>			the second s		2011.1.			
	Rh	M	N	S	5	P1,	<u>Lu</u> ª	ĸ	. <u>k</u>	Kp ²	Lea	Leb	Fya	Ey ^o .	Jka	Jk ^b .	Other	IAT	GAIA
1	R ₁ ^w R ₁	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+	0.00	3	3
2	R ₁ R ₁	+	0	+	0	. 4	0	+	.+	0	+	0	. +	0	+	0		3	3
3	R ₂ R ₂	0	+	0	+	3	0	0	+	D	0	+	0	+	+	0	HLA+ Doa-b+	3	3
4	r'r	0	• +	0	+	0.	0	0	+	0	0	+·	+	0	+	+		3	3
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		3	3
6	rr	+	0	0	+	2	0	+	0	0	0	+	0.	+	0	+	200000 0000000	3	3
7	rr	0	+	0	+	1	0	+	.4	0	+	0	0	÷	+	0		3	3
8	rr	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	Cob+	3	3
9	ŕr	0	+	+	0	4	0	0	+	Ó	0	+	0	+	0	4		3	3
10	r	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	3	7
																	Auto	4	
																	Weak control	3	3




Transfusion STULI MÖTTERS

Case 7

- 77 YO male patient man with CLL
 - Regularly transfused every 2 weeks
 - B pos; antibody screen positive






Transfusion STULI MÖTTERS

- 77 YO male patient man with CLL
 - Regularly transfused every 2 weeks
 - B pos R1r K neg; antibody screen positive
 - Eluate is Pan-reactive 3+, normal result for the patient

Lot Number	Rh	С	D	E	C	e	Cw	K	Jka	Jkb
D405 0507	R ₁ R ₁	+	*	0	0	+	0	0	+	0
R405 3597	rr	0	0	0	+	+	0	+	0	+

	Rh	M	N	S	5	P1.	Luª	ĸ	. k	Kp ²	Lea	Leb	Fy	Ey ⁵ .	Jka	Jkb	Other	IAT	EILIAT	AA I	A
1	R ₁ MR ₁	0	+	0	+	0	0	0	+	0	+	0	0	+	0	+		3	3	2	3
2	R ₁ R ₁	+	0	+	0	. 4	0	+	.+	0	÷	0	+	0	÷	0	¥	3	3	7.	2
3	R ₂ R ₂	0	+	0	+	3	0	0	+	0	0	+	0	+	+	0	HLA+ Doa-b+	3	3	0	6
4	str.	-0	• +	0	+	0.	0	0	+	0	0	+·	+	0	+	+		3	3	2	I
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		3	3	3	7
6	rr	+	0	0	+	2	0	+	0	0	0	+	0	+	0	+		3	3	2	T
7	rr	0	+	0	+	1	0	+	4	0	+	0	0	+	+	0	-	3	3	D	10
8	rr	+	0	0	+	0	0	0	+	+	0	÷	+	0	0	+	Cob+	2	3	3	2
9	ŕr	0	+	+	0	4	0	0	+	Ó	0	+	0	+	0	+		3	3	1	C
10	rr	+	0	0	+	4	+	0	+	0	0	· +	+	0	+	0	Cob+	3	7	2	7
																	Auto	4			-
																	Weak control	3	3	3	
	1	1	۱ ــــــــــــــــــــــــــــــــــــ	1																	
			4		lgG		lg	IA			lgM			C3c			C3d (Cti		_	
					4		5)			1			0			3 5				






- 77 YO male patient man with CLL
 - Regularly transfused every 2 weeks
 - B pos R1r K neg; antibody screen positive
 - Eluate is Pan-reactive 3+, normal result for the patient

Lot Number	Rh	С	D	E	c	e	C.	K	Jka	Jkb
D 405 0507	R ₁ R ₁	+	*	0	0	+	0	0	+	0
R405 3597	rr	0	0	0	+	+	0	÷	0	+

		1					1		-			-									<u></u>
ļ	Rh	M				P1.	Lu?	1		Кр		1	Fya	5	1	Jk ^b .	Other	IAT.	EntiA	AA I	AA2
1	R ₁ MR ₁	0		0	-	0	0	0		0		0	0		0	(+)	100	3	3	2	2
2	R ₁ R ₁	(+)	0	+	0	. 4	0	+	+	0	+	0	(+)	0	÷	\bigcirc	v	3	3	7	2
3	R ₂ R ₂	0	$\boldsymbol{\times}$	0	\mathbf{X}	3	0	0	X	D	0	X	0	+		0	HLA+ Doa-b+	3	3	1	5
4	rte	0	• +	0	+	0.	0	0	+	0	0	+.	+	0	+	+		3	3	2	Ĩ
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		3	3	3	Ż
6	rr	(+)	0	0	+	2	0	+	0	0	0	+	0	+	0	(+)		3	3	2	Ī
7	rr	0	+	0	+	1	0		+	0	+	0		+	+			3	3	0	0
8	rr	+	0	0	+	0	0	0	÷	+	0	÷	+	0	0	+	Cob+	2	3	3	2
9	iπ.	0	+		0	4	0	0	+	Ó	0	+	0	+	0	(+)		3	3	IT	5
10	rr	+	0	0	+	4	+	0	+	0	0	+	+	0	+	0	Cob+	3	7	2	7
																	Auto	4			
																	Weak control	3	3	3	
	1	1	1	1	1 1		1							1		T					
						lgG			lgA			lgN	1		C	ic.	C3d		Cti		
						4			0			1			C)	3	1	O		1
					-j							1.1.1			T						4





- 77 YO male patient man with CLL
 - Regularly transfused every 2 weeks
 - B pos R1r K neg; antibody screen positive
 - Eluate is Pan-reactive 3+, normal result for the patient
 - Anti-Jka; ?anti-M; ?anti-Fya
 - Genotype GYPA*01/GYPA*02 = Negative/Positive FY*01/FY*02 = Negative/Positive

JK*01/JK*02 = Negative/Positive

	Rb	M				P1	1			1 10.00			1	1		7		10002		H and M	
		- W					Lu?			Kp*			Fy ^a	1.5	1	Jk ^b .	Other	JAT.	EntiA	AA I	AA2
	R ₁ ^w R ₁	0		0	/	0	0	0	-	0		0	0		0	(+)		3	3	2	E.
2	R ₁ R ₁	(+)	0	+	0	. 4	0	+	+	0	+	0	(+)	0	+	\bigcirc	÷	3	3	7	2
3	R ₂ R ₂		\mathbf{X}	0	$\boldsymbol{\times}$	3	0	0	X	D	0	X	0	+		0	HLA+ Doa-b+	3	3	5	5
4	r'r	-0	+	0	+	0.	0	0	+	0	0	+.	+	0	+	+		3	3	2	Ĭ
5	r"r	+	0	+	0	0	0	0	+	0	0	+	+	0	0	+		3	3	3	7
6	m	+	0	0	+	2	0	+	0	0	0	+	0	+	0	(+)		3	3	2	T
7	rr	0	+	0	+	1	0		+	0	+	0	0	+	+	$\overline{\mathbf{O}}$		3	3	5	0
8	rr	+	0	0	+	0	0	0	+	+	0	÷	+	0	0	+	Cob+	17	3	3	2
9	ŕr	(0)	+	1	0	4	0	0	+	Ó	0	+	$\left(0 \right)$	+	0	(+)		3	3	1	5
10	r	+	0	0	+	4	+	0	+	0	0	• +	+	0	+	0	Cob+	3	7	2	7
																	Auto	4		-	-
																	Weak control	3	3	3	
		1		1	1													1			
				IgG			igA			lgM		C3c		C3d		Cti					
				10			0			1			0				2		0		
					4						••••••••••••••••••••••••••••••••••••••						<u> </u>				
				,	1.777		1												_		



Panel (IAT, EN/IAT)

(1, 2, R1R1, R2R2, DTT)

Adsorption

Elution

Phenotype

Screen

DAT

Rare cell

Donath

Landsteiner

LISS tube

PROTEIN

Genotyping

Inhibition

Neutralisation



Complex Serology

Matt Hazell – Senior Clinical Scientist (HSST) Red Cell Immunohaematology NHSBT







34